The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes’ type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients… Read more
The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid following the U.S. Food and Drug Administration (FDA) approval of the drug on May 2, 2011. Tradjenta was approved as a prescription medication to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes… Read more
The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]).
Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days… Read more
U.S. District Court for the Southern District of California granted Amylin Pharmaceuticals a temporary restraining order (TRO) related to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement… Read more
Amylin Pharmaceuticals announced that it has filed a lawsuit against Eli Lilly. Amylin alleges Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements to maximize commercialization of exenatide currently marketed as BYETTA® (exenatide) injection… Read more
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly’s type 2 diabetes drug Tradjenta (linagliptin) as a medication used along with diet and exercise to lower blood sugar in adult patients.
The drug can be used as monotherapy or in combination with other commonly prescribed medications… Read more
Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Bydureon for injection in the European Union for the treatment of type 2 diabetes in combination with… Read more
Positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes were announced by Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. Exenatide once monthly is a new… Read more
JDRF and Eli Lilly signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate the insulin-producing cells destroyed by the disease. The goal of this research agreement is to understand how selected cells can be reprogrammed in order to convert them into insulin-producing cells in the body. This research is an example of regenerative medicine… Read more
Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as Lilly’s two basal insulin analogues—LY2605541 and LY2963016—as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody…. Read more